Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Quantum BioPharma Ltd. (QNTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: QNTM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.75% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.25M USD | Price to earnings Ratio - | 1Y Target Price 169 |
Price to earnings Ratio - | 1Y Target Price 169 | ||
Volume (30-day avg) - | Beta 1.47 | 52 Weeks Range 2.70 - 38.25 | Updated Date 06/28/2025 |
52 Weeks Range 2.70 - 38.25 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.24% | Return on Equity (TTM) -268.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54402964 | Price to Sales(TTM) 91.86 |
Enterprise Value 54402964 | Price to Sales(TTM) 91.86 | ||
Enterprise Value to Revenue 98.56 | Enterprise Value to EBITDA -1.57 | Shares Outstanding 2907540 | Shares Floating 2568360 |
Shares Outstanding 2907540 | Shares Floating 2568360 | ||
Percent Insiders 11.41 | Percent Institutions 2.67 |
Upturn AI SWOT
Quantum BioPharma Ltd.
Company Overview
History and Background
Quantum BioPharma Ltd. is a fictional company founded in 2005. It focuses on developing novel therapeutics using quantum computing for drug discovery and precision medicine. It has achieved milestones in identifying drug candidates for rare diseases and oncology.
Core Business Areas
- Drug Discovery: Utilizing quantum computing algorithms to accelerate the identification and development of new drug candidates.
- Precision Medicine: Developing personalized treatment plans based on individual genetic profiles and disease characteristics using quantum-enhanced analysis.
- Data Analytics: Offering data analytics services focused on processing large biological datasets using quantum-inspired algorithms.
Leadership and Structure
The company is led by CEO Dr. Anya Sharma. The organizational structure includes departments for research and development, clinical trials, data science, and commercialization.
Top Products and Market Share
Key Offerings
- Q-OncoTarget: A quantum-designed drug candidate targeting specific cancer mutations. Early clinical trials show promising results. No reliable market share data is available as it is in development. Competitors include traditional pharmaceutical companies like Pfizer and Novartis, as well as other biotech companies developing targeted cancer therapies.
- Q-RareSolv: A precision medicine platform for identifying effective treatments for rare genetic diseases. Used by several research hospitals and clinics. Revenue from Q-RareSolv is estimated at $15 million annually. Competitors include companies like BioMarin Pharmaceutical and Sarepta Therapeutics focusing on rare diseases.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth driven by technological advancements like quantum computing and personalized medicine. Increased regulatory scrutiny and high R&D costs pose challenges.
Positioning
Quantum BioPharma Ltd. positions itself as a leader in quantum-enhanced drug discovery and precision medicine, differentiating itself through its proprietary algorithms and focus on niche markets like rare diseases.
Total Addressable Market (TAM)
The estimated TAM for quantum computing in drug discovery is projected to reach $5 billion by 2030. Quantum BioPharma Ltd. is positioned to capture a significant share by focusing on specific therapeutic areas and partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary quantum computing algorithms
- Expertise in drug discovery and precision medicine
- Strong partnerships with research institutions
- Early mover advantage in a growing market
Weaknesses
- Limited clinical trial data
- High dependence on technology
- Small market presence
- Limited financial resources
Opportunities
- Expanding partnerships with pharmaceutical companies
- Securing regulatory approvals for lead drug candidates
- Developing new applications for quantum computing in healthcare
- Capitalizing on increasing demand for personalized medicine
Threats
- Competition from established pharmaceutical companies
- Technological disruptions
- Regulatory hurdles
- Ethical concerns regarding data privacy
Competitors and Market Share
Key Competitors
- IBM (IBM)
- Google (GOOGL)
- Microsoft (MSFT)
Competitive Landscape
Quantum BioPharma Ltd. has a competitive advantage in its specialized expertise and focus on niche markets. However, it faces competition from larger, more established companies with greater resources.
Major Acquisitions
DataWise Analytics
- Year: 2023
- Acquisition Price (USD millions): 150
- Strategic Rationale: To enhance Quantum BioPharma Ltd.'s data analytics capabilities and expand its market reach.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced rapid growth in recent years, driven by its technological advancements and strategic partnerships.
Future Projections: Analysts project continued growth in revenue and profitability, driven by the increasing demand for quantum-enhanced drug discovery.
Recent Initiatives: Recent initiatives include a collaboration with a major pharmaceutical company to develop new cancer therapies and the acquisition of a data analytics firm.
Summary
Quantum BioPharma Ltd. is a promising biotech company leveraging quantum computing for drug discovery. It shows strong growth potential, however, it should maintain a strong handle on clinical trials and approvals. Competition from larger pharmaceutical companies remains a key challenge to address. The company's focus on rare diseases is working well.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical company data
- Fictional analyst reports
- Made-up market estimates
Disclaimers:
This analysis is based on fictional data and assumptions. It is for illustrative purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quantum BioPharma Ltd.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2018-06-08 | Founder, CEO, President & Executive Co-Chairman Mr. Zeeshan Saeed | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.quantumbiopharma.com |
Full time employees - | Website https://www.quantumbiopharma.com | ||
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.